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Abstract: Recently, it has been shown that HCV core proteins (HCcAg) with C-terminal deletions 
assemble in vitro into virus-like particles (VLPs) in the presence of structured RNA molecules. Results 
presented in this work showed that a truncated HCcAg variant covering the first 120 aa (HCcAg.120) 
with  a  32  aa  N-terminal  fusion  peptide  (6xHistag-Xpress
TMepitope)  interacts  with  plasmid  DNA 
vaccine. Interestingly, the buoyant density of VLPs containing HCcAg.120 in CsCl gradients changed 
from 1.15-1,17 g mL￿
1 to 1.30-1.34 g mL￿
1 after addition of plasmid DNA to assembly reactions. In 
addition,  a  delay  in  electrophoretic  mobility  of  HCcAg.120-plasmid  samples  on  agarose  gels  was 
observed indicating a direct interaction between VLPs and nucleic acids. Remarkably, addition of 
either  plasmid  DNA  or  tRNA  to  assembly  reactions  leaded  to  heterogeneous  and  larger  VLPs 
formation  than  those  observed  in  HCcAg.120  assembly  reactions.  VLPs  containing  HCcAg.120 
induced a specific IgG antibodies in mice that reacted with hepatocytes from HCV-infected patients. 
VLPs obtained in this work would be important to elucidate the mechanisms behind the ability of 
HCcAg  to  assemble  into  a  nucleocapsid  structure.  Besides,  the  capacity  of  particles  containing 
HCcAg.120 to interact with nucleic acids could be used in the development of DNA vaccines and viral 
vectors based on these particles.  
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INTRODUCTION 
 
  Hepatitis  C  virus  (HCV)  is  a  major  worldwide 
health problem.
 HCV is a member of the Hepacivirus 
genus  of  the  Flaviviridae
  family
[1].  The  genome  is  a 
single-stranded  positive-sense
  RNA  of  approximately 
9600 nt and encodes a polyprotein
 with a single open 
reading  frame  (ORF)  of  3008–3033 aa  which  is 
processed by host and viral proteases
[2]. The structural 
proteins (core, E1,
 E2 and potentially p7) precede the 
nonstructural proteins (NS2,
 3, 4A, 4B, 5A and 5B) in 
the polyprotein. The biogenesis of HCV core protein 
(HCcAg) is dependent on the interaction of the signal 
sequence of nascent polypeptide with the endoplasmic 
reticulum  (ER)  membrane
[3].  Although  it  has  been 
suggested that HCcAg function to encapsidate the viral 
genome within a nucleocapsid particle, little is known 
about the in vivo assembly pathway or structure of the 
HCV nucleocapsid and virion
[4].  
  Since  virion  nucleocapsid  formation  involves 
multimerization of HCcAg and its interaction with viral 
RNA,  these  characteristics  of  HCcAg  have  been 
extensively   studied   and  specific functions mapped to  
 
discrete  portions  of  the  molecule
[5-8].  Difficulties  in 
obtaining  mature  HCcAg  have  required  that  core 
proteins with C-terminal deletions be used for in vitro 
functional  studies
[9-11].  In  addition,  these  HCcAg 
variants  self-assemble  into  nucleocapsids  in  cell-free 
assays in the presence of structured nucleic acids
[9,11]. 
However, there are still many questions open about the 
assembly properties of HCcAg. 
  Previously, it has been reported that a C-terminal 
truncated  HCcAg  variant  (covering  aa  1-120)  with  a 
6xHis  tag  fusion  at  N-terminus  (HCcAg.120) 
assembled  into  virus-like  particles  (VLPs)  when 
expressed      in      recombinant      Escherichia      coli  
cells
[10]. On   the   other   hand,  a   previous   study   
had   demonstrated   that   a DNA vaccine containing 
the  structural  region  of  HCV  (pIDKE2  plasmid) 
induces    a    strong    humoral    and    cellular    immune 
response  in  various  animal  models
[12,13].  Since 
particulate  antigens  have been proposed as potential 
carriers  for  DNA  vaccines
[14],  the  capacity  of 
HCcAg.120  to  interact  with  pIDKE2  plasmid  and  to 
assemble  into  VLPs  in   vitro   was  investigated  in 
this study. Am. J. Infect. Diseases, 1 (1):66-72, 2005 
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MATERIALS AND METHODS 
 
Plasmid, antibodies and strain: The pIDKE2 plasmid 
containing the structural region of HCV (HCcAg, E1 
and E2) has been previously described
[12]. It was used 
in  protein-nucleic  acid  interaction  studies.  A  mouse 
monoclonal  antibody  against  the  residues  5-35  of 
HCcAg  (mAb  SS-HepC.1)  was  used  to  detect 
HCcAg.120
[15].  Anti-HCcAg.120  IgG  antibodies 
obtained  in  mice  immunized  with  VLPs  containing 
HCcAg.120  were  used  in  immunoelectron  and 
immunofluorescence  microscopy  analysis.  The 
BL21(DE3)pLysS  strain  was  used  to  express 
HCcAg.120 as previously reported
[10]. 
 
HCcAg.120  purification  from  recombinant 
Escherichia  coli  cells:  HCcAg.120  was  semipurified 
under  denaturing  conditions  with  purity  higher  than 
85% as previously described
[10]. Later on, HCcAg.120 
in denaturing buffer (DB) (8M urea, 20 Mm Tris-HCL 
pH 8, 250 mM NaCl) was applied to reverse-phase (RP) 
high-pressure  liquid  chromatography  (HPLC)  C8 
column (either 4.6 x 150 mm or 10 x 250 mm) (Vydac 
HPLC columns, USA) as previously described
[9,16]. It 
was eluted using a linear gradient of acetonitrile (AcN) 
in 5% trifluoroacetic acid (TFA) at 1 mL min ￿
1 flow 
rate. The major eluted fraction containing HCcAg.120 
was  dialyzed  overnight  at  4°C  against  TNGU  buffer 
(20 mM  Tris  [pH  7.0],  100 mM  NaCl,  1%  Glycerol, 
2 M Urea). Later on, HCcAg.120 was concentrated by 
30% ammonium sulfate precipitation and resuspended 
at 2 mg mL￿
1 in TNGU buffer. Finally, HCcAg.120 was 
dialyzed overnight at 4°C against refolding buffer (RB) 
(20 mM Tris [pH 7.0], 100 mM NaCl, 1% Glycerol). 
Renatured HCcAg.120 sample (after a 16,000 g spin at 
4°C for 15 min) was tested in three percent agarose gels 
prepared in 20 mM Tris-acetate-0.5 mM EDTA (TA) 
buffer  and  stained  with  TA  buffer  containing  10  ug 
mL￿
1 of ethidium bromide. HCcAg.120 was purified as 
a single protein with purity higher than 90 %. 
 
HCcAg.120-pIDKE2 plasmid interaction studies: In 
vitro  protein-nucleic  acids  assembly  reactions  were 
carried out using conditions  previously described
[9,11]. 
Ten  micromolar  of  purified  HCcAg.120  in  renatured 
buffer  was  mixed  with  an  equal  volume  of  pIDKE2 
plasmid at 100:1 protein-nucleic acid molar ratio. As 
control,  denatured  HCcAg.120  was  resuspended  in 
refolding  buffer  containing  tRNA  (Sigma)  at  100:1 
protein-nucleic  acid  molar  ratio  under  RNase-free 
conditions. The reactions were incubated at 30 ºC for 
10 min followed by 15 min on ice and a 16,000 g spin 
at 4°C for 15 min. 
 
Equilibrium  density  gradient  centrifugation:  Five 
hundred  microlitre  of  either  renatured  HCcAg.120  or 
HCcAg.120-pIDKE2 plasmid samples were applied to 
a discontinuous 1-1.5 g  mL￿
1 cesium chloride (CsCl) 
density  gradient  in  the  same  buffer  of  the  protein 
sample,  centrifuged  at  100  000  g  for  26  h  in  a 
Beckmann  SW40Ti  rotor  and  fractionated.  Five 
hundred  microlitre  aliquot  of  each  fraction  was 
collected from the bottom of the tube. Samples  were 
also  separated  on  a  linear  25-70  %  sucrose  density 
gradient solution and centrifuged at 100 000 g for 16 h. 
The  refractive  index  of  each  fraction  was  measured 
using  an  Abbe-3L  refractometer  (Milton  Roy).  To 
detect   HCcAg.120,   fractions   were   assayed   by  
Dot   blot   as   previously   reported
[17].  The  intensity 
of      the      resultant    bands    was    quantified    by  
measuring the optical density with the Eagle Eye II still 
video system (Stratagene).  
 
Agarose  gel  electrophoresis:  Samples  containing 
either  pIDKE2  plasmid  or  HCcAg.120-pIDKE2 
plasmid  were  analyzed  on  agarose  gel  as  previously 
described
[18]. The sample was mixed with 5X loading 
buffer  (50%  glycerol,  0,02%  bromophenol  blue)  and 
loaded onto a 1% agarose gel with ethidium bromide 
(0.5 mg mL￿
1). The gel was run in 1X TAE buffer and 
the gel was either detected under UV light or stained 
with Coomassie brilliant blue R250 (CBB, Sigma, St. 
Louis, USA). 
 
Transmission  electron  microscopy  (TEM):  Either 
renatured  HCcAg.120,  or  pIDKE2  plasmid,  or 
HCcAg.120/pIDKE2  plasmid,  or  HCcAg.120/tRNA 
were  fixed  in  glutaraldehyde  and  negatively  stained 
with  uranyl  acetate  prior  to  analysis  by  transmission 
electron microscopy as previously described
[15].  
 
Detection  of  HCV  core  protein  inhepatocytes:  For 
Immunoelectron  microscopy  (IEM)  analysis,  samples 
of  liver  tissue  from  either  HCV-infected  patients  or 
healthy  individuals
[19]  were  fixed  with  4%  (v/v) 
paraformaldehyde containing 0.2% (v/v) glutaraldehyde 
in 0.1 M phosphate buffer (pH 7.3) at 4 ºC for 3 h and 
washed with 0.1 M phosphate buffer. Fixed cells were 
dehydrated as described above, embedded in Lowicryl 
and  polymerized  by  exposure  to  ultraviolet  light  at 
room temperature for 72 h. Ultrathin sections of liver 
biopsies  were  incubated  with  anti-HCcAg.120  IgG 
antibodies  in  phosphate  buffer,  for  45  min  at  RT. 
Specific  reactions  were  detected  as  previously 
described
[19].  For  immunofluorescence  staining  (IF) 
analysis,  samples  were  immediately  fixed  with  4% 
paraformaldehyde in PBS at 4 ºC and then mounted on 
gelatine-coated glass slides and stored for 2 days at -
200 ºC.  Then  samples  were  treated  as  previously 
described
[20] and incubated overnight at 4 ºC with with 
anti-HCcAg.120  IgG  antibodies.  Specific  reactions 
were  detected  as  described  elsewhere
[20].  Stained 
samples  were  coverslipped  in  Vectashield  mountaing 
medium  (Vector  Laboratories,  Inc.  Burlingame,  CA., 
USA),  sealed  with  nail  polish  and  viewed  on  an 
immunofluorescence microscope. Am. J. Infect. Diseases, 1 (1):66-72, 2005 
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Statistical  analyses:  All  data  were  presented  as 
mean±SE.  Comparison  of  diameters  of  VLPs  was 
conducted by Kruskal-Wallis test and Dunn’s post test 
with  GraphPad  PRISM  4.0  software.  p<0.05  was 
considered statistically significant. 
 
RESULTS AND DISCUSSION 
 
  Previous  studies  had  demonstrated  that  HCcAg 
bound  to  the  60S  ribosomal  subunit  and  RNA  in 
vitro
[3,6,7,21].  In  addition,  Kunkel  et  al  have  suggested 
that  interaction  between  HCcAg  and  nucleic  acids  in 
vitro plays a critical role for self-assembly of HCcAg 
into  VLPs
[9].  They  also  suggested  that  HCcAg  can 
undergo  extensive  conformational  changes  upon 
binding to nucleic acid and assembly into VLPs
[22].  
  On  the  other  hand,  a  previous  study  had 
demonstrated  that  a  DNA  vaccine  containing  the 
structural region of HCV (pIDKE2 plasmid) induces a 
strong  humoral  and  cellular  immune  response  in 
various animal models
[12,13]. Since particulate antigens 
have  been  proposed  as  potential  carriers  for  DNA 
vaccines
[14], the capacity of HCcAg.120 to interact with 
pIDKE2 plasmid was investigated.  
  HCcAg.120  was  mixed  with  pIDKE2  plasmid  at 
100:1  protein-nucleic  acid  molar  ratio  as  described 
above.  Firstly,  a  density  gradient  centrifugation  was 
used to demonstrate a possible interaction of pIDKE2 
plasmid  with  HCcAg.120  in  the  VLPs  assembly 
reactions.  We  expected  that  VLPs  containing 
HCcAg.120 either in the presence or in the absence of 
pIDKE2  plasmid  should  differ  in  buoyant  density 
according to their nucleic acids content.  
  As  shown  in  Fig.  1,  the  CsCl  gradient  was 
fractionated and the individual fractions assayed for the 
presence of HCcAg.120. A peak fraction containing the 
renatured  HCcAg.120  in  the  absence  of  pIDKE2 
plasmid  that  migrated  to  a  position  in  the  gradient 
corresponding to a buoyant density of 1.15-1.17 g mL￿
1 
was  observed  (Fig.  1A).  Interestingly,  the 
sedimentation  behavior  of  HCcAg.120  changed  from 
1.15-1.17 g mL￿
1 to 1.30-1.34 g mL￿
1 in HCcAg.120-
pIDKE2  plasmid  samples,  indicating  a  possible 
interaction between VLPs containing HCcAg.120 and 
pIDKE2 plasmid (Fig. 1B). Similarly, sucrose gradient 
analysis  showed  high  density  sucrose  fractions 
containing  HCcAg  in  HCcAg.120-pIDKE2  plasmid 
samples (not shown). 
  These high density HCcAg.120 fractions were only 
observed  in  HCcAg.120-pIDKE2  plasmid  samples. 
This is in agreement with previous results showing that 
native  core-like  particles  containing  nucleic  acids 
obtained from recombinant E. coli and Pichia pastoris 
cells  migrate  with  buoyant  densities  values  ranging 
from 1.28 g mL￿
1 to 1.32 g mL￿
1 in CsCl and sucrose 
gradients
[10,11,15].  It  is  interesting  to  note  that  native 
nucleocapsid  particles  from  sera  of  HCV-infected 
patients   show  high  buoyant  density values in sucrose  
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Fig. 1: CsCl  gradient  centrifugation  analysis.  The  CsCl 
density of each fraction is shown (open circles; density 
(left  ordinate)  expressed  in  grams  per  milliliter). 
Detection  of  HCcAg.120  was  analyzed  by 
densitometry of dot blot (closed triangles; HCcAg.120 
(right ordinate) expressed as signal (OD) at 620 nm). 
A) Analysis of renatured HCcAg.120. B) Analysis of 
HCcAg.120-pIDKE2 plasmid samples  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Presence  and  characteristics  of  HCcAg.120-pIDKE2 
from  CsCl  fractions  (12-14). 1%  agarose  gel  of  the 
HCcAg.120-pIDKE2  complexes  visualized  with 
ethidium  bromide  (A)  and  Comassie  Blue  (B).  The 
lanes  contain:  pIDKE2  plasmid  (1);  CsCl  fractions 
(12-14)  containing  HCcAg.120-pIDKE2  complexes 
(2-4, respectively); 1 Kb PlusLadder
TM (Gibco BRL) 
size markers (5) 
 
and  CsCl  gradients
[4,23].  In  addition,  nucleocapsid 
particles obtained after detergent treatment from sera of 
chimpanzees and humans  with chronic non-A,  non-B 
hepatitis,  have  shown  similar  buoyant  density 
values
[4,24].  Data  suggest  that  samples  containing 
HCcAg.120-pIDKE2 plasmid showed similar buoyant 
density  values  to  those  previously  observed  for 
nucleocapsids found in HCV-infected patients.  
1   2    3    4   5   1    2    3   4   5  
B   A  
12 Kb 
 
2 Kb 
 
0.1 Kb Am. J. Infect. Diseases, 1 (1):66-72, 2005 
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Fig. 3: Transmission electron microscopy images of samples 
containing  HCcAg.120.  Micrograph  of  negatively 
stained samples containing: A) CsCl fractions (1.15-
1.17  g  mL￿
1)  containing  renatured  HCcAg.120  B) 
HCcAg.120-pIDKE2 plasmid C) pIDKE2 plasmid D) 
HCcAg.120-tRNA. Bar 200 nm 
 
  Afterwards,  gradient  fractions  of  HCcAg.120-
pIDKE2  plasmid  samples  were  electrophoresed  on 
0.5% agarose gels and stained with EtBr. The formation 
of HCcAg.120-pIDKE2 plasmid complexes are shown 
in Fig. 2. Intense EtBr staining was seen in all the cases. 
A  delay  in  electrophoretic  mobility  of  HCcAg.120-
pIDKE2 samples was observed (Fig. 2A). EtBr-stained 
bands  were  also  positive  for  Coomasie  staining, 
indicating that these were indeed HCcAg.120-pIDKE2 
complexes (Fig. 2B). 
  In  addition,  assembly  reactions  containing 
HCcAg.120  were  analyzed  by  TEM.  Homogeneous 
particles with an average diameter of approximately 30 
nm  (29.91  nm,  SD  5,84)  were  observed  for  gradient 
fractions containing renatured HCcAg.120 (1.15-1.17 g 
mL￿
1),  indicating  that  CsCl  and  sucrose  gradient 
conditions did not affect the VLPs (Fig. 3A). Figure 4A 
shows the frequency distribution of particle diameters. 
The diameters of these particles ranged from 20 to 41 
nm.  Remarkably,  renatured  HCcAg.120  (present  in 
HCcAg.120-pIDKE2 plasmid samples) assembled into 
larger  and  heterogeneous  VLPs  (average  diameter  of 
78.63 nm, SD 29.59) (Fig. 3B and 4D).  
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Fig. 4: Histogram representing the frequency distribution of 
particle diameters observed by TEM in the assembly 
experiments of HCcAg.120. The diameter of particles 
was precisely measured in at least 10 fields (from 250 
to 500 VLPs) from electron micrographs. Diameters 
of VLPs derived from renatured HCcAg.120 (A) or 
HCcAg.120-pIDKE2  plasmid  (B)  or  HCcAg.120-
tRNA (C) are shown. (D) Comparison of diameters of 
VLPs  from  different  in  vitro  assembly  reactions 
containing HCcAg.120. (a) HCcAg-pIDKE2,HCcAg-
tRNA>HCcAg,  p<0.001;  (b)  HCcAg-
pIDKE2>HCcAg-tRNA, p<0.05 
 
Figure 4B shows the frequency distribution of particle 
diameters. The diameters of these particles ranged from 
36 to 190 nm. However, these VLPs were not observed  Am. J. Infect. Diseases, 1 (1):66-72, 2005 
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A      B 
 
Fig. 5: Immunolabeling  of  HCcAg  in  hepatocytes  of  liver 
biopsies from HCV-infected patients by IEM. A) No 
immunostaining was observed in hepatocytes of liver 
biopsies from healthy individuals. B) Immunostaining 
(arrows) of liver sections from HCV-infected patients 
revealed  HCcAg  in  cytoplasm  and  nucleus  of 
hepatocytes. Nucleus (N); Mitochondria (M); Rough 
endoplasmic reticulum (RER). (Bar=1 mm) 
 
in pIDKE2 plasmid samples (Fig. 3C). It is interesting 
to  note  that  HCcAg.120  also  assembled  into 
heterogeneous  VLPs  in  the  presence  of  tRNA 
molecules (average diameter of 59.89 nm, SD 20.16) 
(Fig.  3D  and  4C).  The  diameters  of  these  particles 
ranged from 25 to 100 nm. These particles were larger 
than  those  obtained  in  HCcAg.120-only  assembly 
reactions  but  shorter  than  those  observed  in 
HCcAg.120-pIDKE2      plasmid      assembly  reactions 
(Fig. 4D). 
  Finally, IEM (Fig. 5) and IF analysis (not shown) 
showed that anti-HCcAg.120 IgG antibodies, obtained 
in mice immunized with VLPs containing HCcAg.120 
(not  shown),  speciffically  reacted  with  hepatocytes 
from  HCV-infected  patients  but  not  with  hepatocytes 
from healthy individuals. This suggest that these VLPs 
share epitopes with the HCcAg expressed during HCV 
infection in hepatocytes.  
  Previously,  in  vitro  assembly  of  a  C-terminal 
truncated HCcAg (covering the first 124 aa) into VLPs 
using a purified recombinant protein from E. coli was 
observed  only  in  the  presence  of  structured  RNA
[9]. 
These VLPs were heterogenous in size and larger than 
the  expected  native  HCV  nucleocapsids.  HCcAg.120 
assembled into homogeneous VLPs in the absence of 
structured  nucleic  acids.  However,  addition  of  either 
pIDKE2  plasmid  or  tRNA  molecules  to  assembly 
reactions  leaded  to  larger  and  heterogenous  VLPs 
which appeared similar to those previously described
[9]. 
One   hypothesis   is  that  the  denaturation-renaturation  
 
process  partially  affected  the  folding  of  the  protein 
which leads to the formation of larger agglomerates in 
the  presence  of  nucleic  acids.  Indeed  a  recent  report 
describes the purification of various variants of HCcAg 
under native conditions
[11]. HCcAg assembled in vitro 
into VLPs with similar size and appearance to native 
HCV nucleocapsids in the presence of structured RNA. 
In addition, only the first 79 N-terminal aa of HCcAg 
assembled  in  vitro  into  homogeneous  particles  of 
regular  size  and  shape  in  the  presence  of  structured 
tRNA.  However,  a  few  contaminants  copurified  with 
the recombinant proteins and their contribution to the 
VLPs assembly should be studied
[11].  
  Another  hypothesis  would  be  that  nucleic  acids 
misdirect in vitro assembly of VLPs. Misdirectors are 
postulated  to  disturb  the  geometry  of  intersubunit 
contacts  and  convert  a  growing  spherical  polymer, 
which  will  incorporate  only  a  few  hundred  subunits, 
into  a  polymer  that  can  incorporate  an  unlimited 
number
[25,26].  A  misdirector  not  only  should  prevent 
subunits from forming spherical particles but also could 
lead  to  the  formation  of  regular  nonnative 
structures
[25,26]. Thus, it is possible that misdirection of 
VLPs  assembly  by  nucleic  acids  leads  to  large  and 
heterogenous VLPs formation. 
  Therefore, it is not clear why HCcAg assembled in 
vitro  in  the  presence  of  nucleic  acids  into  particles 
larger  than  those  isolated  from  infected  subjects.  In 
vivo, it has been suggested that HCcAg interaction with 
cell membranes or lipids and/or envelope glycoproteins 
may  be  required  for  correct  viral  particle 
morphogenesis
[18,27]. So, it is possible that some cellular 
factors might be required for proper in vitro assembly 
of nucleocapsid-like particles. 
 
CONCLUSION 
 
Results presented in this work showed that interaction 
of HCcAg.120 with plasmid DNA and tRNA leads to in 
vitro assembly of heterogeneous VLPs. This approach 
would  be  important  to  elucidate  the  mechanisms  and 
cellular  factors  that  might  be  required  for  proper  in 
vitro assembly of nucleocapsid-like particles. Besides, 
the  capacity  of  particles  containing  HCcAg.120  to 
interact  with  nucleic  acids  could  be  used  in  the 
development of DNA vaccines and viral vectors based 
on these particles. 
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